研究单位：[1]Peking University Cancer Hospital & Institute[2]Beijing Cancer Hospital Beijing,Beijing,China,100142[3]West China Hospital,Sichuan University Chengdu,Sichuan,China,610041[4]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[5]Zhejiang Cancer Hospital Hangzhou,Zhejiang,China,310022
研究目的：
This study was designed to analyze the prognosis and recurrence predictive factors of high risk patients (Clinical Risk Score≥3) of resectable colorectal liver metastasis.
The efficacy of perioperative chemotherapy plus cetuximab and chemotherapy alone was compared for these patients.
